# Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

> **NCT07050732** · PHASE2 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 170 (estimated)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** Arexvy (2 doses total)
- **BIOLOGICAL:** Arexvy (3 doses total)
- **BIOLOGICAL:** Arexvy (1 dose total)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07050732
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-04
- **Primary completion:** 2026-11
- **Final completion:** 2028-04
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07050732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07050732, "Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT07050732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*